Collaboration, License and Research Agreements - Additional Information (Details)	1 Months Ended	12 Months Ended
	Apr. 30, 2019 USD ($) Product	Dec. 31, 2022 USD ($) Obligation	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue		$ 9,224,000	$ 9,326,000	$ 6,787,000
Research Collaboration and License Agreement with Eli Lilly
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fees received	$ 20,000,000
License agreement expiry period	10 years
Number of performance obligation | Obligation		1
Period for expects performance obligation		5 years
Contract with customer, asset, cumulative catch-up adjustment to revenue, change in measure of progress		$ 1,000,000
Collaboration revenue		9,000,000	9,100,000	$ 6,800,000
Collaboration receivables		$ 2,100,000	$ 900,000
Research Collaboration and License Agreement with Eli Lilly | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Rights to antibody oligonucleotide conjugates for messengers RNA targets. | Product	6
Development milestone payment eligible to receive per target	$ 60,000,000
Regulatory milestone payment eligible to receive per target	140,000,000
Commercialization milestone payment eligible to receive	$ 205,000,000